DBD is expected to report earnings to rise 44.55% to $1.59 per share on November 05
Q3'26
Est.
$1.59
Q2'26
Missed
by $0.13
Q1'26
Beat
by $0.05
Q4'25
Beat
by $1.30
Q3'25
Beat
by $0.28
The last earnings report on July 29 showed earnings per share of $1.10, missing the estimate of $1.23. With 214.63K shares outstanding, the current market capitalization sits at 2.31B.
A.I.dvisor indicates that over the last year, DBD has been loosely correlated with GDRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DBD jumps, then GDRX could also see price increases.
DBD in downward trend: 10-day moving average broke below 50-day moving average on August 04, 2026
The 10-day moving average for DBD crossed bearishly below the 50-day moving average on August 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
DBD moved below its 50-day moving average on July 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for DBD entered a downward trend on September 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DBD's RSI Oscillator exited the oversold zone, of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 26 cases where DBD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on September 02, 2026. You may want to consider a long position or call options on DBD as a result. In of 52 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for DBD just turned positive on August 28, 2026. Looking at past instances where DBD's MACD turned positive, the stock continued to rise in of 31 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .
DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.388) is normal, around the industry mean (28.403). P/E Ratio (22.579) is within average values for comparable stocks, (78.285). DBD's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.665). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.637) is also within normal values, averaging (75.859).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. DBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
